BRIEF—Teijin in-licenses three hormone therapy drugs from Ascendis

Japanese drugmaker Teijin Pharma as enter into an exclusive licensing agreement with Denmark’s Ascendis Pharma regarding the research, development, manufacturing and sales in Japan.

The deal covers TransCon hGH, TransCon PTH, and TransCon CNP, three drugs currently under development as hormone therapy drugs to be used for the treatment of rare endocrine diseases.

Teijin will pay Ascendis a one-off lump-sum contract fee of $70 million (around 9.9 billion yen) and will also pay a maximum of $175 million when achieving development milestones, milestones depending on sales, and royalty fees for sales. three drugs currently under development as hormone therapy drugs to be used for the treatment of rare endocrine diseases.

The company plans to submit an application for the authorization ahead of sales to conduct domestic clinical trials, and to manufacture and sell the drugs.